21st Century Oncology of Las Vegas Introduces Lung Cancer Fighting Technology
Stereotactic Body Radiotherapy promises fewer treatments, greater accuracy and better outcomes for lung cancer patients
LAS VEGAS – Nov. 13, 2013 - November is Lung Cancer Awareness Month and 21st Century Oncology of Las Vegas, part of the nation’s premier cancer treatment network, is announcing a new, shorter radiation therapy option for selected types of lung cancer. It is called Varian® RapidArc® Stereotactic Body Radiotherapy (SBRT) and it treats tumors in less than three minutes over one to five sessions, instead of six to eight weeks of treatment.
SBRT is a type of radiation therapy that combines extremely accurate image-guided tumor targeting with exact patient positioning. This allows higher doses of radiation to be delivered in fewer treatment sessions. The sessions are pain-free and require no sedation, so patients can return to their normal activities right away.
“Because of the pinpoint accuracy of this technology, SBRT can deliver higher doses of targeted radiation in fewer treatment sessions, minimizing exposure to surrounding healthy tissue,” says Brian Lawenda, M.D., Board Certified Radiation Oncologist and 21st Century Oncology of Las Vegas Medical Director. “For qualifying lung cancer patients, this treatment may better fit their needs.”
SBRT treatments are delivered under image guidance, allowing the team to see any movements in the tumor and adjust the radiation beams as needed. The treatment machines can even adjust for the motion of a patient’s breathing, a technique called respiratory gating. The goal is to deliver an effective dosage that is so precisely targeted that it only affects cancerous cells and leaves the healthy tissue surrounding the tumor untouched.
In addition to lung cancer, SBRT is also effective in treating cancers of the liver and prostate.
For more information about our services, visit call XXX-XXX-XXXX.
About 21st Century Oncology:
21st Century Oncology is the largest global, physician led provider of Integrated Cancer Care Services. The Company offers a comprehensive range of cancer treatment services, focused on delivering academic quality, cost-effective patient care in personal and convenient settings. Including the Oncure Transaction, the Company operates 166treatment centers, including 133 centers located in 16 U.S. states. The Company also operates 33 centers located in six countries in Latin America. The Company holds market leading positions in most of its domestic local markets and abroad.
###